Genetic Testing: 6 Key Indications & What They Reveal

Genetic testing serves distinct clinical purposes. The six major categories:

  1. Carrier Screening – Identifies asymptomatic carriers of recessive/X-linked conditions (CF, SMA, Tay-Sachs, thalassemia) for reproductive planning. Pan-ethnic or ancestry-based panels.
  2. Diagnostic Testing – Confirms/specifies a suspected genetic disorder in a symptomatic individual (e.g., chromosomal microarray for developmental delay, gene panel for cardiomyopathy).
  3. Predictive/Presymptomatic Testing – Assesses future risk in asymptomatic at-risk adults (e.g., Huntington disease, BRCA1/2, Lynch syndrome). Requires pre/post-test counseling.
  4. Pharmacogenomics (PGx) – Guides drug selection/dosing based on metabolic genotype (e.g., CYP2C19/clopidogrel, TPMT/thiopurines, DPYD/5-FU). Growing formulary integration.
  5. Prenatal Testing – Detects fetal aneuploidy (NIPT, cfDNA), structural variants (CMA), or monogenic disorders (amnio/CVS) in at-risk pregnancies.
  6. Newborn Screening (NBS) – Universal heel-stick panel (35+ core conditions: metabolic, endocrine, hemoglobin, immunodeficiency, SMA) for pre-symptomatic intervention.

Cross-Cutting Considerations

  • Informed consent, privacy (GINA), variant interpretation (VUS), family implications, equitable access.

Testing must be indication-driven, not recreational. Genetic counseling is standard of care for all but NBS.

Genetic Disorders - Related Articles